The top-ranked vaccine model (V1) showed stable binding to human TLR4 and was predicted to elicit both humoral and cell-mediated immune responses.
Frontiers in Immunology · 10 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The top-ranked vaccine model (V1) showed stable binding to human TLR4 and was predicted to elicit both humoral and cell-mediated immune responses.
Five extracellular parasite proteins were prioritized, and overlapping MHC-I, MHC-II, and linear B-cell epitopes were predicted based on antigenicity, non-allergenicity, and non-toxicity. Four multi-epitope constructs incorporating adjuvant sequences were designed. The vaccine model V1 demonstrated the strongest predicted binding affinity to human TLR4 via molecular docking and molecular dynamics simulations, suggesting stable interaction. In silico immune simulations predicted that V1 could stimulate helper T cells, memory B and T cells, and strong Ig production. The work provides a theoretical framework for future preclinical development but does not report experimental testing.